

## PEACOCK, MYERS &amp; ADAMS, P.C.

INTELLECTUAL PROPERTY LAW SERVICES

Deborah A. Peacock, P.E.<sup>1,2</sup>Jeffrey D. Myers<sup>1,2</sup>Paul Adams<sup>1,2,3</sup>Rod D. Baker<sup>1,2</sup>Stephen A. Slusher<sup>1</sup>Katy C. Fain<sup>1,4</sup>Marcia Thayer Nass<sup>5</sup>

P.O. Box 26927

Albuquerque, New Mexico 87125-6927

Suite 1340

201 Third Street, N.W.

Albuquerque, New Mexico 87102-3368

<sup>1</sup> Registered U.S. Patent and Trademark Office  
Admitted New Mexico Bar

<sup>2</sup> Admitted Colorado Bar

<sup>3</sup> Admitted California, Washington Bars

<sup>4</sup> Admitted Illinois Bar

<sup>5</sup> Admitted New Mexico, California and  
New York Bars

Telephone (505) 998-1500

Fax (505) 243-2542

Email: info@PeacockLaw.com

http://www.PeacockLaw.com

## FAX COVER SHEET

January 23, 2003

Group 1644

TO: Examiner A. DeCloux

FIRM: U.S. Patent and Trademark Office

DOCUMENT: Informal Communication re 09/308,150

FROM: Stephen A. Slusher Reg. No. 43,524

TOTAL NUMBER OF PAGES (INCLUDING COVER SHEET): 3

FAX NO.: 703 306 5824

305 3014

MESSAGE☒ Original will not follow☐ Original will follow via:

- ☐ First-class mail  
☐ Overnight delivery  
☐ Hand delivery

CLIENT # 30394

MATTER # 1027

Please telephone Rometa or Rick at 998-1500 if you do not receive or cannot clearly read the information transmitted herewith. Our return fax number is 243-2542. This message is intended only for the use of the individual or entity to which it is addressed and may contain information that is privileged, confidential and exempt from disclosure under applicable law. If the reader is not the intended recipient, or the employee or agent responsible for delivering the message to the intended recipient, you are hereby notified that any dissemination, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please notify us immediately by telephone, and return the original message to us at the above address via the U.S. Postal Service. Thank you.

FaxForm.doc

#27

INFORMAL COMMUNICATION  
PATENT APPLICATION

## PEACOCK, MYERS &amp; ADAMS, P.C.

INTELLECTUAL PROPERTY LAW SERVICES

Deborah A. Peacock, P.E.<sup>1,3</sup>Jeffrey D. Myers<sup>1,3</sup>Paul Adams<sup>1,2,3</sup>Rod D. Baker<sup>1,3</sup>Stephen A. Slusher<sup>1</sup>Andrea L. Mays<sup>1</sup>Katy C. Fain<sup>1,4</sup>Marcia Thayer Nass<sup>5</sup>1. Registered U.S. Patent and Trademark Office  
Admitted New Mexico Bar

2. Admitted California and Washington Bars

3. Admitted Colorado Bar

4. Admitted Illinois Bar

5. Admitted New Mexico, California and  
New York Bars305-3014  
Via FAX 703-306-5824

January 23, 2003

U.S. and International  
 Patent searches and protection  
 Trademark searches and protection  
 Copyright searches and registrations  
 Intellectual property litigation  
 Licensing of intellectual property  
 Health, medical and FDA law  
 Contracts and product development  
 Employment agreements  
 Confidentiality/Non-compete agreements  
 Computer law  
 Trade secrets  
 Art law

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): Waltherus J.W. van Venrooij, et al.

Serial No. 09/308,150

Examiner: A. DeCloux

Filed: September 30, 1999

Group Art Unit: 1644

For: PEPTIDE DERIVED FROM AN ANTIGEN  
 RECOGNIZED BY AUTOANTIBODIES FROM  
 PATIENTS WITH RHEUMATOID ARTHRITIS,  
 ANTIBODY DIRECTED AGAINST SAID PEPTIDE,  
 A COMBINATORIAL ANTIGEN, AND A METHOD  
 OF DETECTING AUTOIMMUNE ANTIBODIES

INFORMAL COMMUNICATION

Assistant Commissioner for Patents  
 Washington, D.C. 20231

Dear Examiner DeCloux:

This letter is an informal communication pursuant to our telephone call yesterday.

We have filed a request for a corrected filing receipt, adding Gerardus Antonius Schellekens as an inventor. You will ascertain whether Applicant's Petition under 37 CFR § 1.47(a), mailed September 30, 1999, was ever acted upon, and if not, what steps need to be taken. Please feel free to call me if we need to take any action in this regard.

On the issue of modification of the arginine site chain, in addition to citrulline, Applicant has disclosed other specific side chain alterations. See page 10, line 29 through page 11, line 11. Modification of the arginine side chain as described by the formula at page 10 is well known; for example, methyl arginine (where x is NHCH<sub>3</sub> and y is NH) has been described in the literature since at least 1974.

ALBUQUERQUE:  
 201 Third Street NW Suite 1340  
 Post Office Box 26927  
 Albuquerque, New Mexico 87125-6927  
 Telephone: (505) 998-1500  
 Fax: (505) 243-2542

Email: Info@PeacockLaw.com  
 http://www.PeacockLaw.com

SAN DIEGO:  
 501 West Broadway 15th Floor  
 San Diego, California 92101  
 Telephone: (619) 220-0030  
 Fax: (619) 220-0050

Ser. No. 09/308,150

With respect to Serre, et al., U.S. 5,888,833, the only mention of citrulline is as part of a description of filaggrin. Col. 5, lines 15-24. Identification of a 40 KD protein (Col. 26, lines 46-54) does not anticipate specific short sequences or small peptides (under 21 amino acids). Serre, et al., does not disclose any specific peptides of 21 or fewer amino acids, much less any peptide (or indeed protein) including a modified arginine.

Please feel free to give me a call; I've calendared to touch base with you next week.

Respectfully submitted,



Stephen A. Slusher, Reg. No. 43,924  
Direct line: (505) 998-6130

[G:\AMDS\Los&Stig\VanVenrooij\InfComm.doc] 30394-1027